Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Codexis stock | $28.33

Learn how to easily invest in Codexis stock.

Codexis Inc is a biotechnology business based in the US. Codexis shares (CDXS) are listed on the NASDAQ and all prices are listed in US Dollars. Codexis employs 181 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Codexis

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CDXS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Codexis stock price (NASDAQ: CDXS)

Use our graph to track the performance of CDXS stocks over time.

Codexis shares at a glance

Information last updated 2021-10-16.
Latest market close$28.33
52-week range$12.79 - $32.42
50-day moving average $26.72
200-day moving average $23.14
Wall St. target price$30.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.38

Buy Codexis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Codexis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Codexis price performance over time

Historical closes compared with the close of $28.33 from 2021-10-15

1 week (2021-10-11) -4.55%
1 month (2021-09-17) 10.75%
3 months (2021-07-16) 43.81%
6 months (2021-04-16) 20.04%
1 year (2020-10-16) 101.35%
2 years (2019-10-18) 110.48%
3 years (2018-10-18) 79.08%
5 years (2016-10-18) 509.25%

Codexis financials

Revenue TTM $82.9 million
Gross profit TTM $11.1 million
Return on assets TTM -8.34%
Return on equity TTM -18.13%
Profit margin -28.16%
Book value $2.52
Market capitalisation $1.8 billion

TTM: trailing 12 months

Shorting Codexis shares

There are currently 6.6 million Codexis shares held short by investors – that's known as Codexis's "short interest". This figure is 0.8% down from 6.7 million last month.

There are a few different ways that this level of interest in shorting Codexis shares can be evaluated.

Codexis's "short interest ratio" (SIR)

Codexis's "short interest ratio" (SIR) is the quantity of Codexis shares currently shorted divided by the average quantity of Codexis shares traded daily (recently around 291871.29018054). Codexis's SIR currently stands at 22.71. In other words for every 100,000 Codexis shares traded daily on the market, roughly 22710 shares are currently held short.

However Codexis's short interest can also be evaluated against the total number of Codexis shares, or, against the total number of tradable Codexis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Codexis's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Codexis shares in existence, roughly 100 shares are currently held short) or 0.121% of the tradable shares (for every 100,000 tradable Codexis shares, roughly 121 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Codexis.

Find out more about how you can short Codexis stock.

Codexis share dividends

We're not expecting Codexis to pay a dividend over the next 12 months.

Codexis share price volatility

Over the last 12 months, Codexis's shares have ranged in value from as little as $12.79 up to $32.42. A popular way to gauge a stock's volatility is its "beta".

CDXS.US volatility(beta: 1.34)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Codexis's is 1.3429. This would suggest that Codexis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Codexis overview

Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients.

Frequently asked questions

What percentage of Codexis is owned by insiders or institutions?
Currently 2.624% of Codexis shares are held by insiders and 100.535% by institutions.
How many people work for Codexis?
Latest data suggests 181 work at Codexis.
When does the fiscal year end for Codexis?
Codexis's fiscal year ends in December.
Where is Codexis based?
Codexis's address is: 200 Penobscot Drive, Redwood City, CA, United States, 94063
What is Codexis's ISIN number?
Codexis's international securities identification number is: US1920051067
What is Codexis's CUSIP number?
Codexis's Committee on Uniform Securities Identification Procedures number is: 192005106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site